Armin Schulz
Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.
After graduating, he worked as an IT consultant for a listed company before becoming self-employed, during which time he worked for various DAX-listed companies and a large Swiss insurance company, among others.
Since 2009, he has been exclusively involved in the capital markets, where he was able to gain experience as a day and swing trader, in investor relations and at board level. He was able to live out his passion for numbers in the controlling department of a securities trading house.
For him, fundamental analysis paired with the correct reading of the price action of a market provides the basis for successful trading.
Commented by Armin Schulz
Commented by Armin Schulz on March 9th, 2022 | 13:14 CET
BP, Saturn Oil + Gas, Shell - Oil as the winner of the crisis
There are increasing signs that the EU wants to free itself from Russian oil and gas supplies as quickly as possible. Bloomberg writes that they want to cut back supplies by 80% within a year. Other sources report over 66%. If Russia is subject to an oil and gas embargo, there is a risk that commodity prices in these areas will continue to rise significantly. Even the US is currently considering an import ban on Russian oil. Since then, there has been no stopping the oil price. The primary beneficiaries are the oil and gas producers, three of which we are taking a closer look at today.
Read
Commented by Armin Schulz on March 7th, 2022 | 13:05 CET
Valneva, Defence Therapeutics, MorphoSys - Blockbuster potential
Every pharmaceutical or biotech company wants a blockbuster. This term refers to a drug that generates annual sales of at least USD 1 billion. The best-known blockbuster drug currently is the Corona vaccine from BioNTech. In 2020, the rheumatism drug Humira was in the top spot with sales of over USD 20 billion. The Mainz-based vaccine manufacturer is likely to have significantly surpassed this mark in 2021. If a company hits the big time, it can reap the rewards for 20 years before the patent expires. Today, we take a look at three companies that have potential blockbusters.
Read
Commented by Armin Schulz on March 4th, 2022 | 12:33 CET
K+S, Phoenix Copper, Barrick Gold - Commodities as portfolio boosters
Prices for raw materials went through the roof last year. On the one hand, the global economy recovered faster than expected. On the other hand, demand for copper increased significantly, especially due to the turnaround in the automotive industry. Now, raw materials are becoming scarce again, as Russia is partially eliminated as an exporter of raw materials. It means that supply is lagging behind demand and resulting in rising prices. Especially for oil, gas and wheat, supply is expected to tighten significantly. Today we present three exciting commodity companies that could benefit from the crisis.
Read
Commented by Armin Schulz on March 2nd, 2022 | 11:24 CET
BioNTech, XPhyto Therapeutics, Valneva - Where are the Corona winners?
Even if the Corona coverage, which has prevailed for 2 years, has recently been replaced by the Ukraine conflict, the pandemic is not yet over. RKI chief Wieler recently reported increased outbreaks in nursing homes and rising incidences among the elderly. Health Minister Lauterbach also sees the wave not yet broken and reports the highest death rates in months. Since the legal basis for the Corona measures expires on March 19, a new law has been introduced to allow measures to be enacted beyond that date. Which companies could benefit?
Read
Commented by Armin Schulz on February 28th, 2022 | 12:43 CET
Alibaba, Hong Lai Huat, BYD - Asia as a safe haven for investments?
The war in Ukraine is causing falling stock indices on both sides. The sanctions against Russia will be extensive; even Nord Stream 2 has been stopped for the time being, although Olaf Scholz did not want to name the pipeline for a long time when it came to possible sanctions. Many countries are calling for Russia to be excluded from the SWIFT system. However, this would mean that many countries would be harming themselves, as energy imports from Russia would no longer be affordable. The war will have losers on both sides. Investors who still want to make their money work for them can take a closer look at companies from the Asian region. China is neutral in the showdown. Which stocks offer opportunities?
Read
Commented by Armin Schulz on February 23rd, 2022 | 11:00 CET
TeamViewer, Aspermont, Delivery Hero - Digital turnaround candidates in check
The prospect of an end to the Corona pandemic and raising interest rates was poison for many companies pursuing a digital business model. Many stocks were fundamentally priced expensively and offered the potential for setbacks for that reason alone. In addition, growth is expected to slow once people start going out more after the pandemic. This outlook is not at all palatable to investors. With the recent Ukraine crisis, pressure is building up once again, and it could be a good time to get one or the other turnaround candidate into the portfolio. Today we take a closer look at three companies.
Read
Commented by Armin Schulz on February 21st, 2022 | 13:48 CET
Palantir, Kleos Space, Lufthansa - Security as a megatrend
The topic of security is becoming increasingly important in all areas of our lives. Whether it is building security, corona measures, IT security or retail security companies, almost all areas have been growing for years. In recent times, there are always new crises to master, such as the refugee crisis, the Corona Crisis or currently the Ukraine crisis. People have a permanent feeling of insecurity. The more digital the world becomes, the more critical security for companies and states becomes. Today, we look at three companies for which security is important.
Read
Commented by Armin Schulz on February 18th, 2022 | 09:42 CET
Nel ASA, First Hydrogen, Plug Power - Hydrogen facing new hype?
In January 2021, the sky was full of violins for the shareholders of hydrogen shares. But shortly after, disillusionment set in, and anyone who jumped on the bandwagon too late is still suffering massive price losses today if they didn't get out in time. Since the end of fossil fuels is a done deal, the industry and the transport sector need an alternative. The German government sees green hydrogen as an essential building block for the energy transition in the future. For this reason, the National Hydrogen Strategy was launched and endowed with EUR 9 billion. There is also support for companies in other countries. Today we look at three companies in the hydrogen sector.
Read
Commented by Armin Schulz on February 16th, 2022 | 10:59 CET
Valneva, Cardiol Therapeutics, Pfizer - Great opportunities after setbacks
First, vaccine maker stocks were pushed down by fears of a pandemic ending by the Omicron variant. Add to that a nervous and challenging market environment that has to deal with interest rate hikes and inflation. Late last week, news that Russia's invasion of Ukraine was imminent added further worry lines. All of this is weighing on the markets, but these setbacks also offer investors opportunities. Today, we analyze three turnaround candidates in more detail.
Read
Commented by Armin Schulz on February 14th, 2022 | 11:56 CET
ThyssenKrupp, Defense Metals, Mercedes-Benz Group - Is war coming now?
The situation around Ukraine is coming to a head. Last Friday, US citizens were called upon to leave Ukraine immediately. US intelligence services suspect that Russia's invasion could be imminent as early as next Wednesday. Stock markets fell in response. But will Russia really start a war? That remains to be seen, but it is clear that war is also an economic engine, despite the suffering it causes. The defense industry needs rare earths, as does the steel and automotive industries. We highlight three companies around rare earths.
Read